



U.S. Food and Drug Administration
Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
FAX: (973) 331-4969
www.fda.gov

July 31, 2019

(b) (6)
(b) (4)

Dear (b) (6) :

The U.S. Food and Drug Administration (FDA) conducted an inspection at (b) (4). FDA has determined that the inspection classification of this facility is "no action indicated ("NAI").¹ Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

¹ See Inspection Classification Definitions, at <https://www.fda.gov/ICECI/Inspections/ucm223231.htm>.

Office of Pharmaceutical Quality Operations, Division of Pharmaceutical Quality Operations I

New England District Office: One Montvale Avenue, 4th Floor Stoneham, MA 02180-3500 T- (781) 587-7500 F- (781) 587-7556

New York District Office: 158-15 Liberty Ave. Jamaica, NY 11433 T-(718) 340-7000 F-(718) 662-5661

Philadelphia District Office: US Customs House Room 900, 200 Chestnut St. Philadelphia, PA 19106 T-(215) 597-4390 F-(215) 597-4660

Baltimore District Office: 6000 Metro Drive, Suite 101 Baltimore, MD 21215 T-410-779-5455 F- 410-779-5407

Page 2

If you have any questions regarding this letter, you may contact Margaret M. Sands, Supervisory Consumer Safety Officer via telephone at (781) 587-7483 or email at Margaret.Sands@fda.hhs.gov.

Sincerely,

Margaret
M. Sands-S

Digitally signed by Margaret M. Sands-S
DN: cn=Margaret M. Sands-S, o=FDA, ou=CDR, email=Margaret.Sands-S@fda.hhs.gov, c=US

Margaret M. Sands
Supervisory Consumer Safety Officer
Division of Pharmaceutical Quality Operations 1
1 Montvale Avenue
Stoneham, MA 02180

ms

Enclosure 1